Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BAL BHANDARI

NPI
1063473494
CMS profile
139171
Location
BASTROP, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,238.94

68 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,238.94 68

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BAL BHANDARI

NPI 1063473494 · CMS profile ID 139171

BASTROP, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063473494?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BAL BHANDARI, NPI 1063473494, CMS profile ID 139171. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063473494?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BAL BHANDARI, NPI 1063473494, CMS profile ID 139171. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063473494?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BAL BHANDARI, NPI 1063473494, CMS profile ID 139171, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1063473494?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

68 matching records · $1,238.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 68 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–68 of 68.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
QOL Medical, LLC $24.8004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185022300 CMS
Ardelyx, Inc. $9.5204/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247835554 CMS
GENZYME CORPORATION $21.1104/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233443927 CMS
Ardelyx, Inc. $31.9204/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247835552 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.4304/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223828484 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.3503/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231814213 CMS
QOL Medical, LLC $27.0603/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185022262 CMS
Ardelyx, Inc. $27.6303/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247835550 CMS
Aimmune Therapeutics, Inc. $15.5403/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249721414 CMS
ABBVIE INC. $14.4903/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512798 CMS
ABBVIE INC. $12.5903/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512796 CMS
Ardelyx, Inc. $21.8003/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247835548 CMS
ABBVIE INC. $10.0902/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512794 CMS
Aimmune Therapeutics, Inc. $16.3502/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249721416 CMS
ABBVIE INC. $8.0601/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512792 CMS
Ardelyx, Inc. $17.5101/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247835546 CMS
ABBVIE INC. $6.9901/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201512790 CMS
Ardelyx, Inc. $16.7701/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247835544 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $585.70 58
PY2020 $449.14 28
PY2021 $1,187.02 106
PY2022 $1,004.76 73
PY2023 $955.08 67
PY2024 $1,076.84 66
PY2025 $1,238.94 68

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,747,428.69 469
PY2024 Principal investigator $358,169.60 88
PY2023 Principal investigator $402,152.75 30
PY2022 Principal investigator $512,933.83 14
PY2021 Recipient $15,988.37 3
PY2021 Principal investigator $825,664.98 92
PY2020 Recipient $4,142.35 3
PY2020 Principal investigator $1,045,584.77 147
PY2019 Recipient $31,086.49 6
PY2019 Principal investigator $1,458,580.19 175

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

469 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644581
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644597
Principal investigator 1 Boehringer Ingelheim International GmbH $71.55 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644599
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644615
Principal investigator 1 Boehringer Ingelheim International GmbH $87.75 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644623
Principal investigator 1 Boehringer Ingelheim International GmbH $70.20 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644627
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644629
Principal investigator 1 Boehringer Ingelheim International GmbH $924.75 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644633
Principal investigator 1 Boehringer Ingelheim International GmbH $2,358.45 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644635
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644643
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644645
Principal investigator 1 Boehringer Ingelheim International GmbH $71.55 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644647
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644653
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644655
Principal investigator 1 Eli Lilly and Company $8,600.00 12/30/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES (SYNERGY-OUTCOMES); N1T-MC-TZ01; N1T-MC-RT01 No dispute reported 06/30/2026 1187880405
Principal investigator 1 Boehringer Ingelheim International GmbH $1,861.65 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644229
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644231
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644233
Principal investigator 1 Boehringer Ingelheim International GmbH $1,861.65 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644235
Principal investigator 1 Boehringer Ingelheim International GmbH $1,861.65 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644237
Principal investigator 1 Boehringer Ingelheim International GmbH $2,623.05 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644239
Principal investigator 1 Boehringer Ingelheim International GmbH $1,861.65 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644241
Principal investigator 1 Boehringer Ingelheim International GmbH $1,861.65 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644243
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644245
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644253
Principal investigator 1 Boehringer Ingelheim International GmbH $4.47 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644255
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644257
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644259
Principal investigator 1 Boehringer Ingelheim International GmbH $20.20 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644265
Principal investigator 1 Boehringer Ingelheim International GmbH $195.00 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644267
Principal investigator 1 Boehringer Ingelheim International GmbH $2,623.05 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644269
Principal investigator 1 Boehringer Ingelheim International GmbH $2,188.35 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644271
Principal investigator 1 Boehringer Ingelheim International GmbH $11,878.65 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644273
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644275
Principal investigator 1 Boehringer Ingelheim International GmbH $2,623.05 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644277
Principal investigator 1 Boehringer Ingelheim International GmbH $2,188.35 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644279
Principal investigator 1 Boehringer Ingelheim International GmbH $16,119.00 12/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644281
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644261
Principal investigator 1 Boehringer Ingelheim International GmbH $17,550.00 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644585
Principal investigator 1 Boehringer Ingelheim International GmbH $1,941.30 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644591
Principal investigator 1 Boehringer Ingelheim International GmbH $792.45 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644593
Principal investigator 1 Boehringer Ingelheim International GmbH $1,941.30 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644601
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644605
Principal investigator 1 Boehringer Ingelheim International GmbH $1,941.30 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644607
Principal investigator 1 Boehringer Ingelheim International GmbH $5,059.80 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644611
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644621
Principal investigator 1 Boehringer Ingelheim International GmbH $1,941.30 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644625
Principal investigator 1 Boehringer Ingelheim International GmbH $17,550.00 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644639
Principal investigator 1 Boehringer Ingelheim International GmbH $2,268.00 12/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644651
Principal investigator 1 Madrigal Pharmaceuticals $18,711.70 12/19/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254677
Principal investigator 1 Boehringer Ingelheim International GmbH $14,742.92 12/18/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644251
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 12/18/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644263
Principal investigator 1 Boehringer Ingelheim International GmbH $399.68 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644247
Principal investigator 1 Boehringer Ingelheim International GmbH $1,578.30 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644249
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644291
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644293
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644295
Principal investigator 1 Boehringer Ingelheim International GmbH $29.31 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644297
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644299
Principal investigator 1 Boehringer Ingelheim International GmbH $3.64 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644641
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644667
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644669
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 12/17/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644671
Principal investigator 1 Eli Lilly and Company $934.02 12/17/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187882464
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187882466
Principal investigator 1 Madrigal Pharmaceuticals $1,620.00 12/11/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254111
Principal investigator 1 Madrigal Pharmaceuticals $75.00 12/11/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254115
Principal investigator 1 Madrigal Pharmaceuticals $2,084.06 12/11/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254119
Principal investigator 1 Boehringer Ingelheim International GmbH $40.50 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644583
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644587
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644589
Principal investigator 1 Boehringer Ingelheim International GmbH $87.75 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644595
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644603
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644609
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644613
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644617
Principal investigator 1 Boehringer Ingelheim International GmbH $70.20 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644619
Principal investigator 1 Boehringer Ingelheim International GmbH $70.20 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644631
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644637
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 12/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644649
Principal investigator 1 Madrigal Pharmaceuticals $2,423.93 12/04/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253558
Principal investigator 1 Madrigal Pharmaceuticals $8,336.24 11/25/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253030
Principal investigator 1 Boehringer Ingelheim International GmbH $472.50 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644177
Principal investigator 1 Boehringer Ingelheim International GmbH $205.20 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644179
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644191
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644193
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644197
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644203
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644209
Principal investigator 1 Boehringer Ingelheim International GmbH $472.50 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644211
Principal investigator 1 Boehringer Ingelheim International GmbH $472.50 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644215
Principal investigator 1 Boehringer Ingelheim International GmbH $47.25 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644221
Principal investigator 1 Boehringer Ingelheim International GmbH $472.50 11/21/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644227
Principal investigator 1 Boehringer Ingelheim International GmbH $70.20 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644181
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644201
Principal investigator 1 Boehringer Ingelheim International GmbH $47.25 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644207
Principal investigator 1 Boehringer Ingelheim International GmbH $70.20 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644213
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644217
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644219
Principal investigator 1 Boehringer Ingelheim International GmbH $71.55 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644223
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644225
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644283
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644285
Principal investigator 1 Boehringer Ingelheim International GmbH $1,204.50 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644287
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644289
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644661
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644663
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 11/19/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644665
Principal investigator 1 Madrigal Pharmaceuticals $411.75 11/17/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248252678
Principal investigator 1 Madrigal Pharmaceuticals $4,507.99 11/14/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252653
Principal investigator 1 Madrigal Pharmaceuticals $9,015.98 11/07/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252561
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 11/06/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644577
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 11/06/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644579
Principal investigator 1 Boehringer Ingelheim International GmbH $4,201.45 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644173
Principal investigator 1 Boehringer Ingelheim International GmbH $4,610.35 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644175
Principal investigator 1 Boehringer Ingelheim International GmbH $4,674.15 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644183
Principal investigator 1 Boehringer Ingelheim International GmbH $4,615.35 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644185
Principal investigator 1 Boehringer Ingelheim International GmbH $4,679.15 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644187
Principal investigator 1 Boehringer Ingelheim International GmbH $1,077.35 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644189
Principal investigator 1 Boehringer Ingelheim International GmbH $580.00 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644195
Principal investigator 1 Boehringer Ingelheim International GmbH $4,674.15 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644199
Principal investigator 1 Boehringer Ingelheim International GmbH $4,610.35 11/05/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644205
Principal investigator 1 GlaxoSmithKline, LLC. $1,831.31 11/05/2025 Non-covered Recipient Entity
DELTA RESARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157919
Principal investigator 1 Madrigal Pharmaceuticals $4,168.12 10/29/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252222
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644549
Principal investigator 1 Boehringer Ingelheim International GmbH $2,259.90 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644551
Principal investigator 1 Boehringer Ingelheim International GmbH $15,682.95 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644553
Principal investigator 1 Boehringer Ingelheim International GmbH $2,621.70 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644555
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644557
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644559
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644561
Principal investigator 1 Boehringer Ingelheim International GmbH $24,528.15 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644563
Principal investigator 1 Boehringer Ingelheim International GmbH $24,528.15 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644565
Principal investigator 1 Boehringer Ingelheim International GmbH $15,682.95 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644567
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644569
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644571
Principal investigator 1 Boehringer Ingelheim International GmbH $2,619.00 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644573
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644575
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644657
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644659
Principal investigator 1 Madrigal Pharmaceuticals $24,390.15 10/24/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248252079
Principal investigator 1 Madrigal Pharmaceuticals $7,275.00 10/23/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248252043
Principal investigator 1 Madrigal Pharmaceuticals $1,000.00 10/23/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252048
Principal investigator 1 Madrigal Pharmaceuticals $26,673.90 10/23/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE No dispute reported 06/30/2026 1248252052
Principal investigator 1 Madrigal Pharmaceuticals $7,425.00 10/23/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252056
Principal investigator 1 Madrigal Pharmaceuticals $8,676.11 10/23/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252059
Principal investigator 1 Madrigal Pharmaceuticals $4,847.86 10/09/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251477
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 10/08/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644141
Principal investigator 1 Boehringer Ingelheim International GmbH $195.00 10/08/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644145
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 10/08/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644149
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 10/08/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644163
Principal investigator 1 Boehringer Ingelheim International GmbH $4.47 10/08/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644165
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 10/08/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644167
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 10/08/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644169
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 10/08/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644171
Principal investigator 1 Boehringer Ingelheim International GmbH $190.50 10/03/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644143
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 10/03/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644147
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 10/03/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644151
Principal investigator 1 Boehringer Ingelheim International GmbH $4.47 10/03/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644153
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 10/03/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644155
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 10/03/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644157
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 10/03/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644159
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 10/03/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644161
Principal investigator 1 Madrigal Pharmaceuticals $5,722.50 10/03/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251276
Principal investigator 1 Madrigal Pharmaceuticals $6,592.05 10/03/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251280
Principal investigator 1 Boehringer Ingelheim International GmbH $2,619.00 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644481
Principal investigator 1 Boehringer Ingelheim International GmbH $2,259.90 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644489
Principal investigator 1 Boehringer Ingelheim International GmbH $24,528.15 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644495
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644497
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644499
Principal investigator 1 Boehringer Ingelheim International GmbH $15,682.95 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644501
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644503
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644507
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644513
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644515
Principal investigator 1 Boehringer Ingelheim International GmbH $15,550.65 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644519
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644523
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644529
Principal investigator 1 Boehringer Ingelheim International GmbH $2,259.90 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644533
Principal investigator 1 Boehringer Ingelheim International GmbH $7,265.70 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644535
Principal investigator 1 Boehringer Ingelheim International GmbH $24,528.15 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644537
Principal investigator 1 Boehringer Ingelheim International GmbH $3,192.75 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644539
Principal investigator 1 Boehringer Ingelheim International GmbH $2,621.70 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644541
Principal investigator 1 Boehringer Ingelheim International GmbH $1,933.20 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644543
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644545
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 09/29/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644547
Principal investigator 1 Boehringer Ingelheim International GmbH $15,882.75 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644093
Principal investigator 1 Boehringer Ingelheim International GmbH $11,920.50 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644099
Principal investigator 1 Boehringer Ingelheim International GmbH $11,920.50 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644103
Principal investigator 1 Boehringer Ingelheim International GmbH $2,180.25 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644105
Principal investigator 1 Boehringer Ingelheim International GmbH $11,920.50 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644107
Principal investigator 1 Boehringer Ingelheim International GmbH $2,180.25 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644115
Principal investigator 1 Boehringer Ingelheim International GmbH $15,882.75 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644117
Principal investigator 1 Boehringer Ingelheim International GmbH $15,882.75 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644121
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644123
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644127
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 09/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644129
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 09/24/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644085
Principal investigator 1 Boehringer Ingelheim International GmbH $29.31 09/24/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644087
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 09/24/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644477
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644479
Principal investigator 1 Madrigal Pharmaceuticals $6,931.92 09/23/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250510
Principal investigator 1 Madrigal Pharmaceuticals $45,922.50 09/18/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250091
Principal investigator 1 Madrigal Pharmaceuticals $825.00 09/18/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250095
Principal investigator 1 Madrigal Pharmaceuticals $810.00 09/18/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250099
Principal investigator 1 Madrigal Pharmaceuticals $1,540.00 09/18/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250103
Principal investigator 1 Madrigal Pharmaceuticals $11,100.04 09/18/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250107
Principal investigator 1 Boehringer Ingelheim International GmbH $405.00 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644089
Principal investigator 1 Boehringer Ingelheim International GmbH $405.00 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644091
Principal investigator 1 Boehringer Ingelheim International GmbH $157.50 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644095
Principal investigator 1 Boehringer Ingelheim International GmbH $10,280.25 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644097
Principal investigator 1 Boehringer Ingelheim International GmbH $157.50 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644101
Principal investigator 1 Boehringer Ingelheim International GmbH $405.00 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644109
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644111
Principal investigator 1 Boehringer Ingelheim International GmbH $303.75 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644119
Principal investigator 1 Boehringer Ingelheim International GmbH $438.75 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644125
Principal investigator 1 Boehringer Ingelheim International GmbH $10,280.25 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644131
Principal investigator 1 Boehringer Ingelheim International GmbH $10,280.25 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644133
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644135
Principal investigator 1 Boehringer Ingelheim International GmbH $10,077.75 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644137
Principal investigator 1 Boehringer Ingelheim International GmbH $157.50 09/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644139
Principal investigator 1 GlaxoSmithKline, LLC. $101.25 09/17/2025 Non-covered Recipient Entity
DELTA RESARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154826
Principal investigator 1 GlaxoSmithKline, LLC. $74.25 09/17/2025 Non-covered Recipient Entity
DELTA RESARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157923
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 09/17/2025 Non-covered Recipient Entity
DELTA RESARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157932
Principal investigator 1 Madrigal Pharmaceuticals $6,592.05 09/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249875
Principal investigator 1 GlaxoSmithKline, LLC. $9,436.91 09/09/2025 Non-covered Recipient Entity
DELTA RESARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157928
Principal investigator 1 Boehringer Ingelheim International GmbH $71.55 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644483
Principal investigator 1 Boehringer Ingelheim International GmbH $70.20 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644485
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644487
Principal investigator 1 Boehringer Ingelheim International GmbH $364.50 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644491
Principal investigator 1 Boehringer Ingelheim International GmbH $364.50 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644493
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644505
Principal investigator 1 Boehringer Ingelheim International GmbH $364.50 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644509
Principal investigator 1 Boehringer Ingelheim International GmbH $40.50 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644511
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644517
Principal investigator 1 Boehringer Ingelheim International GmbH $70.20 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644521
Principal investigator 1 Boehringer Ingelheim International GmbH $140.40 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644525
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644527
Principal investigator 1 Boehringer Ingelheim International GmbH $70.20 09/04/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644531
Principal investigator 1 Madrigal Pharmaceuticals $2,084.06 09/04/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249390
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 09/03/2025 Non-covered Recipient Entity
DELTA RESARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154821
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 09/03/2025 Non-covered Recipient Entity
DELTA RESARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157915
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 09/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644113
Principal investigator 1 Boehringer Ingelheim International GmbH $18.20 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644429
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644431
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644433
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644435
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644437
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644439
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644441
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644443
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644445
Principal investigator 1 Boehringer Ingelheim International GmbH $122.50 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644447
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644451
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644453
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644455
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644457
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644459
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644461
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644049
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644051
Principal investigator 1 Boehringer Ingelheim International GmbH $2.76 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644053
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644055
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644057
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644059
Principal investigator 1 Boehringer Ingelheim International GmbH $4.47 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644061
Principal investigator 1 Boehringer Ingelheim International GmbH $90.00 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644063
Principal investigator 1 Boehringer Ingelheim International GmbH $124.00 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644065
Principal investigator 1 Boehringer Ingelheim International GmbH $195.00 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644067
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644075
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644077
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644079
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644081
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644083
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644469
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644471
Principal investigator 1 Boehringer Ingelheim International GmbH $766.50 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644473
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 08/26/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644475
Principal investigator 1 Madrigal Pharmaceuticals $4,847.86 08/21/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248829
Principal investigator 1 Boehringer Ingelheim International GmbH $19,899.00 08/20/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644449
Principal investigator 1 Boehringer Ingelheim International GmbH $5,116.50 08/20/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644463
Principal investigator 1 GlaxoSmithKline, LLC. $2,913.88 08/18/2025 Non-covered Recipient Entity
DELTA RESARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157910
Principal investigator 1 Madrigal Pharmaceuticals $7,291.02 08/14/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248341
Principal investigator 1 Madrigal Pharmaceuticals $9,015.98 08/07/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248064
Principal investigator 1 Madrigal Pharmaceuticals $7,271.79 07/31/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247653
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 07/28/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644073
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 07/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644465
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 07/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644467
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644029
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644031
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644033
Principal investigator 1 Boehringer Ingelheim International GmbH $103.69 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644037
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644039
Principal investigator 1 Boehringer Ingelheim International GmbH $62.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644041
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644043
Principal investigator 1 Boehringer Ingelheim International GmbH $36.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644045
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644371
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644393
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644395
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644397
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644409
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644415
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644417
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644423
Principal investigator 1 Madrigal Pharmaceuticals $192,867.50 07/22/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247349
Principal investigator 1 Madrigal Pharmaceuticals $4,847.86 07/22/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247353
Principal investigator 1 GlaxoSmithKline, LLC. $2,341.61 07/21/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158339
Principal investigator 1 Madrigal Pharmaceuticals $2,423.93 07/17/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247105
Principal investigator 1 Boehringer Ingelheim International GmbH $5,547.50 07/16/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644035
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644373
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644375
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644383
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644389
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644391
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644399
Principal investigator 1 Boehringer Ingelheim International GmbH $40.50 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644401
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644405
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644407
Principal investigator 1 Boehringer Ingelheim International GmbH $52.00 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644413
Principal investigator 1 Boehringer Ingelheim International GmbH $40.50 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644419
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 07/11/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644421
Principal investigator 1 Madrigal Pharmaceuticals $4,168.12 07/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246753
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644377
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644379
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644381
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644385
Principal investigator 1 Boehringer Ingelheim International GmbH $87.75 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644387
Principal investigator 1 Boehringer Ingelheim International GmbH $108.00 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644403
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644411
Principal investigator 1 Boehringer Ingelheim International GmbH $40.50 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644425
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 07/09/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644427
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 07/09/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158314
Principal investigator 1 Madrigal Pharmaceuticals $6,931.92 07/04/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246392
Principal investigator 1 Madrigal Pharmaceuticals $450.00 07/04/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246396
Principal investigator 1 Madrigal Pharmaceuticals $15,592.50 07/04/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246400
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644047
Principal investigator 1 Boehringer Ingelheim International GmbH $3,192.75 06/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644321
Principal investigator 1 Boehringer Ingelheim International GmbH $3,192.75 06/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644323
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 06/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644325
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 06/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644327
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 06/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644329
Principal investigator 1 Boehringer Ingelheim International GmbH $3,192.75 06/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644331
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 06/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644333
Principal investigator 1 Boehringer Ingelheim International GmbH $2,259.90 06/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644335
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 06/24/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644355
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 06/24/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644357
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 06/24/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644359
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 06/24/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644361
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 06/24/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644363
Principal investigator 1 Madrigal Pharmaceuticals $9,015.98 06/24/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246164
Principal investigator 1 Madrigal Pharmaceuticals $225.00 06/24/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246167
Principal investigator 1 Madrigal Pharmaceuticals $6,771.60 06/19/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245904
Principal investigator 1 GlaxoSmithKline, LLC. $12,662.73 06/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158324
Principal investigator 1 Madrigal Pharmaceuticals $11,439.91 06/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245526
Principal investigator 1 Madrigal Pharmaceuticals $675.00 06/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245530
Principal investigator 1 Madrigal Pharmaceuticals $6,750.00 06/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245534
Principal investigator 1 Madrigal Pharmaceuticals $2,603.48 06/05/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245060
Principal investigator 1 Madrigal Pharmaceuticals $325.00 06/05/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245064
Principal investigator 1 Madrigal Pharmaceuticals $2,430.00 06/05/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245068
Principal investigator 1 Madrigal Pharmaceuticals $11,610.00 06/05/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245072
Principal investigator 1 Madrigal Pharmaceuticals $375.00 06/05/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245076
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644071
Principal investigator 1 Boehringer Ingelheim International GmbH $15,682.95 05/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644349
Principal investigator 1 Boehringer Ingelheim International GmbH $633.15 05/28/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644353
Principal investigator 1 Madrigal Pharmaceuticals $4,304.00 05/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244691
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 05/27/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644027
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 05/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644367
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 05/27/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644369
Principal investigator 1 GlaxoSmithKline, LLC. $4,584.50 05/26/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157941
Principal investigator 1 Madrigal Pharmaceuticals $8,823.60 05/22/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244324
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 05/15/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644009
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/15/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644011
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 05/15/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644017
Principal investigator 1 Boehringer Ingelheim International GmbH $4,725.00 05/15/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644019
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 05/15/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644021
Principal investigator 1 Boehringer Ingelheim International GmbH $472.50 05/15/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644023
Principal investigator 1 Madrigal Pharmaceuticals $26,547.75 05/15/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243907
Principal investigator 1 Madrigal Pharmaceuticals $450.00 05/15/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243911
Principal investigator 1 Madrigal Pharmaceuticals $51,435.00 05/15/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243915
Principal investigator 1 GlaxoSmithKline, LLC. $40.50 05/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157945
Principal investigator 1 GlaxoSmithKline, LLC. $74.25 05/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158319
Principal investigator 1 GlaxoSmithKline, LLC. $101.50 05/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158332
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 05/12/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158343
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 05/08/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158328
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 05/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644337
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 05/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644339
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 05/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644341
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644343
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 05/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644345
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 05/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644347
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/05/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644351
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 05/02/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644005
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/02/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644007
Principal investigator 1 Boehringer Ingelheim International GmbH $1,170.00 05/02/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644013
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 05/02/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644015
Principal investigator 1 Madrigal Pharmaceuticals $375.00 05/02/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243107
Principal investigator 1 Madrigal Pharmaceuticals $6,480.00 05/02/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243111
Principal investigator 1 Madrigal Pharmaceuticals $300.00 05/02/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243115
Principal investigator 1 Madrigal Pharmaceuticals $875.00 05/02/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243118
Principal investigator 1 Madrigal Pharmaceuticals $7,798.00 05/02/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS OF BASTROP LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243121
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644025
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 04/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644315
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 04/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644317
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 04/30/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644319
Principal investigator 1 GlaxoSmithKline, LLC. $9,995.81 04/25/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192157937
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 04/23/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644365
Principal investigator 1 Madrigal Pharmaceuticals $6,090.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242167
Principal investigator 1 Madrigal Pharmaceuticals $4,427.50 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242170
Principal investigator 1 Madrigal Pharmaceuticals $36,785.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242175
Principal investigator 1 Madrigal Pharmaceuticals $3,780.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242179
Principal investigator 1 Madrigal Pharmaceuticals $275.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242182
Principal investigator 1 Madrigal Pharmaceuticals $4,050.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242186
Principal investigator 1 Madrigal Pharmaceuticals $1,575.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242191
Principal investigator 1 Madrigal Pharmaceuticals $450.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242195
Principal investigator 1 Madrigal Pharmaceuticals $4,522.50 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242200
Principal investigator 1 Madrigal Pharmaceuticals $8,572.50 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242204
Principal investigator 1 Madrigal Pharmaceuticals $75.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242209
Principal investigator 1 Madrigal Pharmaceuticals $7,398.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242213
Principal investigator 1 Madrigal Pharmaceuticals $400.00 04/10/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242218
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 04/09/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643993
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 04/09/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643995
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 04/09/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643999
Principal investigator 1 Madrigal Pharmaceuticals $30,234.97 04/08/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241880
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644003
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 03/25/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643983
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 03/25/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643985
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643987
Principal investigator 1 Boehringer Ingelheim International GmbH $29.31 03/25/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643989
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 03/25/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644311
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 03/25/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644313
Principal investigator 1 GlaxoSmithKline, LLC. $4,573.57 03/21/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192149929
Principal investigator 1 Madrigal Pharmaceuticals $51,615.00 03/20/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241165
Principal investigator 1 Boehringer Ingelheim International GmbH $5,539.50 03/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643977
Principal investigator 1 Boehringer Ingelheim International GmbH $464.50 03/17/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643979
Principal investigator 1 Madrigal Pharmaceuticals $5,670.00 03/13/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240901
Principal investigator 1 Madrigal Pharmaceuticals $325.00 03/06/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240314
Principal investigator 1 Madrigal Pharmaceuticals $1,925.00 03/06/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240319
Principal investigator 1 Madrigal Pharmaceuticals $27,128.74 03/06/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240323
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643991
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 03/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643997
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644001
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 02/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154805
Principal investigator 1 GlaxoSmithKline, LLC. $40.50 02/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158351
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 02/25/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643981
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644301
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644303
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644305
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644307
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Delta Research Partners
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220644309
Principal investigator 1 GlaxoSmithKline, LLC. $16,343.58 02/24/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154813
Principal investigator 1 Madrigal Pharmaceuticals $61,027.74 02/06/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239141
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220644069
Principal investigator 1 Madrigal Pharmaceuticals $500.00 01/30/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238880
Principal investigator 1 Madrigal Pharmaceuticals $1,225.00 01/30/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238885
Principal investigator 1 Madrigal Pharmaceuticals $6,480.00 01/30/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238889
Principal investigator 1 Madrigal Pharmaceuticals $37,290.00 01/30/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238893
Principal investigator 1 Madrigal Pharmaceuticals $7,357.50 01/30/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238897
Principal investigator 1 Madrigal Pharmaceuticals $1,770.00 01/30/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238901
Principal investigator 1 Madrigal Pharmaceuticals $5,848.50 01/30/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238903
Principal investigator 1 GlaxoSmithKline, LLC. $74.25 01/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192103239
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 01/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192149925
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 01/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154793
Principal investigator 1 GlaxoSmithKline, LLC. $40.50 01/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154796
Principal investigator 1 GlaxoSmithKline, LLC. $101.50 01/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154801
Principal investigator 1 GlaxoSmithKline, LLC. $203.00 01/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154809
Principal investigator 1 GlaxoSmithKline, LLC. $19,035.10 01/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192154817
Principal investigator 1 GlaxoSmithKline, LLC. $74.25 01/28/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192158347
Principal investigator 1 Madrigal Pharmaceuticals $75,513.56 01/03/2025 Non-covered Recipient Entity
DELTA RESEARCH PARTNERS LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238025
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Delta Research Partners
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220643975